CLSA Wire

DC Congressional Briefing: Federal Investment in Biomedical Innovation
Facebook
Twitter
LinkedIn

June 23, 2017

On June 5, CLSA hosted a congressional briefing on the importance of funding for the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). The event, convened in collaboration with Reps. Leonard Lance (R-NJ) and Scott Peters (D-San Diego) as co-chairs of the Congressional Life Science Caucus, was co-hosted along with 15 other state and regional life sciences associations.

CLSA secured the expert panelists, including representatives from National Health Council, Alliance for a Stronger FDA, the Association of American Universities and United for Medical Research. The discussion was focused around how the agencies fuel biomedical innovation, work with private industry and academia to advance global human health, and give hope to patients in need. The event attracted a sizeable standing room-only crowd, and was very well attended by congressional staff and other stakeholders.

CLSA continues to support efforts to bolster funding for NIH and other science research agencies, as these agencies provide a critical foundation of the biomedical R&D ecosystem. Earlier this year (March 31), Rep. Susan Davis (D-San Diego) led a bipartisan House letter in support of $36 billion for NIH in the FY18 Labor-HHS Appropriations Bill. CLSA was strongly supportive of the letter, and due to our outreach efforts, the letter was cosigned by 35 other bipartisan members of the California congressional delegation. A copy of the final letter is available here.

Questions? Please contact Jenny Carey, CLSA’s Vice President of Federal Government Relations and Alliance Development (jcarey@califesciences.org).